Last reviewed · How we verify

NCT02775045: EoE

Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

Completed Last updated 30 January 2019
What this trial tests

trial testing Observation Period in Eosinophilic Esophagitis in 28 participants. Completed in 13 December 2018.

Timeline
30 August 2016
Primary endpoint
13 December 2018
13 December 2018

Quick facts

Lead sponsorUniversity of Wisconsin, Madison
StatusCompleted
Study typeOBSERVATIONAL
Enrollment28
Start date30 August 2016
Primary completion13 December 2018
Estimated completion13 December 2018
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Wisconsin, Madison

Who can join

18 and older, any sex, with Eosinophilic Esophagitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to improve the overall management of patients with Eosinophil Esophagitis. Currently, the best way to monitor Eosinophil Esophagitis is repeating the endoscopy procedure. The investigators plan to identify a biomarker in the blood (a measurable substance) that tracks with disease activity and will reduce the need for follow-up endoscopies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Platelet association with leukocytes in active eosinophilic esophagitis.
    Bartig KA, Lee KE, Mosher DF, Mathur SK, et al · · 2021 · cited 3× · PMID 33891621 · DOI 10.1371/journal.pone.0250521

Verify or expand the search:

Other recruiting trials for Eosinophilic Esophagitis

Currently open trials in the same condition.

Other University of Wisconsin, Madison trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02775045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing